Delivery Order SPE2DB22D1106-SPE2DB25FFDM4
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Paclitaxel 300 mg/50 ml vials with a firm fixed price ceiling value of $1,126.20. This delivery order represents a non-set-aside, competitively awarded procurement supporting the federal government's pharmaceutical supply requirements. The award is fulfillment under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a...
- The Defense Logistics Agency awarded a delivery order valued at $4,467.19 to AmerisourceBergen Drug Corp for Paclitaxel Protein-Bound 100mg on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price contract has no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $5,650.26 on August 6, 2025, for Paclitaxel Protein-Bound 100mg pharmaceutical product. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 7, 2025, to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $8,649.54 firm fixed price delivery order to AmerisourceBergen Drug Corp for Paclitaxel Protein-Bound 100mg on September 3, 2025, with an ultimate completion date of September 4, 2025. This non-set-aside delivery order is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under the vendor's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive...
- The Defense Logistics Agency awarded a delivery order valued at $11,596.30 to AmerisourceBergen Drug Corp for the supply of Paclitaxel Protein-Bound 100mg on September 16, 2025, with an ultimate completion date of September 17, 2025. This firm fixed price, non-set-aside contract is being performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $7,085.18 to AmerisourceBergen Drug Corp for Paclitaxel Protein-Bound 100mg on June 17, 2025, with an ultimate completion date of June 18, 2025. The contract employs firm fixed price terms with no set-aside designation, indicating it was competitively awarded. Performance will be executed from the contractor's location in Conshohocken, Pennsylvania. This delivery order represents a small-value transaction within...
- The Defense Logistics Agency awarded a $11,158.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Paclitaxel Protein-Bound 100mg on August 6, 2025, with completion scheduled for August 7, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026 that provides comprehensive global pharmaceutical support for military healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $26,443.36 to AmerisourceBergen Drug Corp for Paclitaxel Protein-Bound 100mg on August 5, 2025, with an ultimate completion date of August 6, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on April 23, 2025, for the supply of Paclitaxel Protein-Bound 100mg, a chemotherapy medication. The delivery order, valued at $8,312.02 with a firm fixed price structure, carries an ultimate completion date of April 24, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp will perform the work at its corporate office location in Conshohocken, Pennsylvania, leveraging its...
- This delivery order, awarded on June 17, 2025, represents a $7,553.38 firm fixed price purchase of Paclitaxel Protein-Bound 100mg pharmaceutical product from AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The award was made by the Defense Logistics Agency (DLA), a Department of Defense component responsible for supply chain management across military operations and healthcare systems. The contract is unclassified as a set-aside and...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFDM4Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,001.16 to AmerisourceBergen Drug Corp for the supply of Paclitaxel 300 mg/50 mL vials on August 14, 2025, with completion targeted for August 15, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award to this major pharmaceutical distributor. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's prime Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending through December 2026. The IDC enables AmerisourceBergen to supply a broad portfolio of pharmaceutical products and medical supplies to support military healthcare programs globally, including medications, vaccines, and specialized medical commodities across multiple therapeutic domains. This particular order for Paclitaxel, a chemotherapy agent, reflects the company's role as a critical vendor supplying specialized pharmaceuticals to the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 8/14/25 |